Strategic Initiative

Slingshot members are tracking this corporate initiative:

Lexicon Pharma (LXRX) Acquires Exclusive Research Rights from Bristol-Myers Squibb (BMY) for Neuropathic Pain Candidate LX9211

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
BMY

100%
LXRX

100%
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Nov 07, 2016
Projected Implementation:
Q4, 2016
Relevance Tracked Until:
Q4, 2018
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Exclusive Research Rights, Neuropathic Pain, Lx9211